Sequenom Inc. (SQNM, $3.38, +$0.40, +13.42%) gained on the back of a Lazard Capital Markets upgrade to hold from sell. The firm sees more reward than risk at its current price, but warns "it is an extremely risky investment with its largest potential stimulus likely over a year away." If a validation study for its controversial Down's syndrome test is successful, the stock could jump to more than $20, the firm said.
upgraded to Buy from stockwolf.com also